Skip to main content

Table 1 All studies included in the meta-analysis

From: Ten-year outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for multivessel or left main coronary artery disease: a systematic review and meta-analysis

Study

SYNTAX

PCI/CABG

PRECOMBAT

PCI/CABG

SOS

PCI/CABG

MASS II

PCI/CABG

LE MANS

PCI/CABG

MAIN-COMPARE

PCI/CABG

ASAN-MAIN PCI/CABG

Nystrom2017

PCI/CABG

Yu2020

PCI/CABG

Study design

RCT

RCT

RCT

RCT

RCT

Observational study

Observational study

Observational study

Observational study

Type of lesion

LMCA/MCAD

LMCA

MCAD

MCAD

LMCA

LMCA

LMCA

NR

LMCA

Patients

903/897

300/300

50/50

205/203

52/53

1102/1138

100/250

1863/683

271/201

Age

65.2 (9.7)/65.0 (9.8)

61.8 (10.0)/62.7 (9.5)

54.7 (8.8)/52.7 (9.1)

60 (9)/60 (9)

60.6 (10.5)/61.3 (8.4)

61.3 (11.7)/62.9 (9.4)

55.1 (10.4)/60.7 (9.1)

61.1 (10.5)/57.2 (10.0)

61.7 (10.3)/60.6 (8.8)

Male sex, %

76.0/79.0

76.0/77.0

80.0/78.0

67.0/72.0

60.0/73.0

70.7/72.9

60.0/74.4)

58.9/63.4

74.2 /76.1

BMI, mean

28.1 (4.8)/27.9 (4.5)

24.6 (2.7)/24.5 (3.0)

NR

NR

NR

NR

24.6 (3.1)/24.6 (2.7)

26.0 (3.9)/26.4 (4.3)

NR

Diabetes mellitus, %

26.0/25.0

34.0/30.0

14.0/18.0

23.0/29.0

19.0/17.0

29.7/34.7

21.0 /32.8

100.0/100.0

28.8/28.9

Hypertension, %

69.0/64.0

54.3/51.3

54.0/42.0

61.0/63.0

75.0/70.0

49.5/49.4

23.0/50.0

NR

56.1/50.2

Hyperlipidemia, %

79.0/77.0

42.3/40.0

46.0/50.0

NR

65.0/60.0

28.6/32.6

34.0/46.0

NR

49.8/38.8

smoker, %

18.0/22.0

29.7 /27.7

44.0/40.0

27.0/32.0

NR

25.6/29.8

36.0/27.2

14.5/15.0

48.3/46.2

previous MI ,%

32.0/34.0

4.3/6.7

38.0/36.0

52.0/41.0

36.0/32.0

8.1/11.6

14.0/16.0

47.6/54.3

17.3/26.9

Previous CVA ,%

4.0/5.0

NR

NR

NR

NR

7.1/7.3

4.0./16.0

9.6/6.6

2.2/14.4

LVEF, %

NR

61.7 ± 8.3

/60.6 ± 8.5

NR

67.0 ± 8.0

/67.0 ± 9.0

53.5 ± 10.7/

53.7 ± 6.7

60.6 ± 10.8

/57.2 ± 11.9

60.3 ± 9.1

/56.8 ± 11.9

NR

64.0 ± 8.1

/62.0.±11.1

LMCA only, %

42/357 (12%)

49/348 (14%)

9.0/11.3

NR

NR

NR

25.2/6.2

55.0/10.4

NR

19.9/7.0

LMCA + SVD, %

67/357 (19%)

71/348 (20%)

16.7/17.7

NR

NR

13.0/6.0

24.0/10.5

21.0/14.4

NR

27.3/15.9

LMCA + DVD, %

112/357 (31%)

106/348 (30%)

33.7/30.0

NR

NR

27.0/19.0

26.0/26.3

16.0/22.4

NR

30.3/25.9

LMCA + TVD, %

136/357 (38%)

122/348 (35%)

40.7/41

NR

NR

60.0/75.0

24.8/57.0

8.0/52.8

NR

22.5/51.2

2-Vessel disease, %

NR

NR

60.0./58.0

42.0/42.0

NR

NR

NR

NR

NR

3-Vessel disease, %

60.0/61.0

NR

40.0/42.0

58.0/58.0

NR

NR

NR

NR

NR

Type of stent

PES

SES

BMS

BMS

BMS/DES

BMS/DES

BMS

NR

DES

  1. Data are presented as percentage treated with PCI/percentage treated with CABG, unless otherwise stated
  2. ASAN-MAIN ASAN Medical Center-Left MAIN Revascularization; BMI Body mass index; BMS Bare metal stent; CVA Cerebrovascular disease; CABG Coronary artery bypass graft; DVD Double-vessel disease; DES Drug-eluting stent; LMCA Left main coronary artery; LVEF Left ventricular ejection fraction; LE MANS Left Main Stenting Trail; MASS-II Medicine, Angioplasty, or Surgery Study; MAIN-COMPARE Revascularization for Unprotected Left Main Coronary ArteryStenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization; MI Myocardial infarction; NR No record; PCI Percutaneous coronary intervention; PES Paclitaxel-eluting stent; PRECOMBAT Premier of Randomized Comparison of Bypass Surgery;. Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; RCT Randomizedcontrolled trial; SVD Single-vessel disease; SES Sirolimus-eluting stent; SOS Stent or Surgery; SYNTAX Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery; TVD Triple-vessel disease
Back to article page

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us